Unexplained skyrocketing of Bright Minds Biosciences stock by nearly 1,500%

On Tuesday, the American stock market session witnessed a massive surge in the shares of the Canadian health and wellness company, Bright Minds Bioscience, headquartered in New York, without any clear justification for the phenomenon.

In terms of trading, the stock listed on the Nasdaq technology index (NASDAQ: DRUG) closed Tuesday's session with an unexplained sharp increase of 1,445.78% or equivalent to $36, reaching $38.49. Meanwhile, the company's stock listed on the Canadian Stock Exchange (CSE: DRUG) closed with an even larger rise of 2,589.63%, recording $44.11 Canadian.

Just a few hours after the market closed, Bright Minds Bioscience released a press statement announcing that its management is not aware of any significant changes in its operations that could be behind this sudden activity witnessed in its shares in the stock markets on Tuesday.

It is worth noting that Bright Minds Bioscience is at the forefront of developing innovative treatments for complex neurological and psychological disorders, epilepsy, and chronic pain, focusing on creating safer and more effective drugs by enhancing the properties of serotonergic compounds.